FOR CLINICIANS
Resources for referring clinicians
Concise, guideline-based summaries for diagnosing obesity, prescribing incretin therapy and assessing metabolic risk, with links to the primary evidence.
Written and reviewed by Farhan Tahir, MD
GRAND ROUNDS
Research updates, appraised for practice
New trials and guideline changes in obesity, diabetes, fatty liver and lipids, with evidence levels and what they mean for patients.
3 GUIDES
Diagnosis & risk
Diagnosis & risk
Diagnosing clinical obesity (Lancet Commission 2025)
Applying the Commission's framework: confirm excess adiposity, then look for organ dysfunction or functional limitation.
Read the guide →
Diagnosis & risk
MASLD screening with FIB-4
Who to screen, how to read FIB-4 and when to refer.
Read the guide →
Diagnosis & risk
ApoB & Lp(a) in risk assessment
When ApoB and Lp(a) change management beyond a standard lipid panel.
Read the guide →
3 GUIDES
Prescribing & monitoring
Prescribing & monitoring
GLP-1 titration & side-effect management
Start low, go slow, and anticipate GI effects, gallbladder risk and lean-mass loss.
Read the guide →
Prescribing & monitoring
Preserving lean mass during weight loss
Practical strategies to limit lean-mass loss with incretin therapy and surgery.
Read the guide →
Prescribing & monitoring
Compounded GLP-1s: FDA status and safety
What changed when the shortages ended, and the safety issues to discuss with patients.
Read the guide →